85.91
0.69%
-0.54
After Hours:
86.43
0.52
+0.61%
Edwards Lifesciences Corp stock is currently priced at $85.91, with a 24-hour trading volume of 2.99M.
It has seen a -0.69% decreased in the last 24 hours and a -8.97% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $86.59 pivot point. If it approaches the $85.84 support level, significant changes may occur.
Edwards Lifesciences Corp Stock (EW) Financials Data
Edwards Lifesciences Corp (EW) Revenue 2024
EW reported a revenue (TTM) of $6.00 billion for the quarter ending December 31, 2023, a +11.56% rise year-over-year.
Edwards Lifesciences Corp (EW) Net Income 2024
EW net income (TTM) was $1.40 billion for the quarter ending December 31, 2023, a -7.85% decrease year-over-year.
Edwards Lifesciences Corp (EW) Cash Flow 2024
EW recorded a free cash flow (TTM) of $629.50 million for the quarter ending December 31, 2023, a -33.97% decrease year-over-year.
Edwards Lifesciences Corp (EW) Earnings per Share 2024
EW earnings per share (TTM) was $2.30 for the quarter ending December 31, 2023, a -5.74% decline year-over-year.
Edwards Lifesciences Corp Stock (EW) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Lippis Daniel J. | CVP, JAPAC |
Apr 09 '24 |
Sale |
92.34 |
857 |
79,135 |
17,488 |
Lemercier Jean-Luc M | CVP, EMEACLA |
Apr 08 '24 |
Option Exercise |
36.75 |
14,400 |
529,200 |
188,249 |
BOBO DONALD E JR | CVP,Strategy/Corp Development |
Apr 08 '24 |
Option Exercise |
36.75 |
12,500 |
459,375 |
52,268 |
Lemercier Jean-Luc M | CVP, EMEACLA |
Apr 08 '24 |
Sale |
92.32 |
14,400 |
1,329,472 |
173,849 |
BOBO DONALD E JR | CVP,Strategy/Corp Development |
Apr 08 '24 |
Sale |
92.33 |
12,500 |
1,154,142 |
39,768 |
MUSSALLEM MICHAEL A | Director |
Apr 04 '24 |
Option Exercise |
36.75 |
29,350 |
1,078,612 |
33,836 |
MUSSALLEM MICHAEL A | Director |
Apr 04 '24 |
Sale |
92.42 |
29,350 |
2,712,418 |
4,486 |
Ullem Scott B. | CVP, Chief Financial Officer |
Apr 01 '24 |
Option Exercise |
36.75 |
7,255 |
266,621 |
26,329 |
Ullem Scott B. | CVP, Chief Financial Officer |
Apr 01 '24 |
Sale |
94.89 |
7,255 |
688,423 |
19,074 |
BOBO DONALD E JR | CVP,Strategy/Corp Development |
Mar 13 '24 |
Option Exercise |
36.75 |
14,500 |
532,875 |
54,003 |
Edwards Lifesciences Corp Stock (EW) Latest News
Will Acute Care Unit Aid Universal Health's (UHS) Q1 Earnings?
Zacks Investment Research
Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth
Zacks Investment Research
Will Humana (HUM) Q1 Earnings Beat on CenterWell Strength?
Zacks Investment Research
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
Zacks Investment Research
Will High Medical Care Ratios Hurt Molina's (MOH) Q1 Earnings?
Zacks Investment Research
Will Low Patient Days Impact Community Health (CYH) Q1 Earnings?
Zacks Investment Research
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.
Cap:
|
Volume (24h):